UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 2)*

MONAKER GROUP, INC.

(Name of Issuer)

COMMON STOCK, PAR VALUE $0.00001 PER SHARE

(Title of Class of Securities)

609011101

(CUSIP Number)

Donald P. Monaco

2690 Weston Road, Suite 200

Weston, FL 33331

Telephone: 630-728-5571

 (Name, Address and Telephone Number of Person

Authorized to Receive Notices and Communications)

August 3, 2017

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

Note : Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “ filed ” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“ Act ”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 
 

 

 
 

 

CUSIP No. 609011101

 

 

 

1

 

NAME OF REPORTING PERSONS.
I.R.S. IDENTIFICATION NO. OF ABOVE  PERSONS (ENTITIES ONLY)

Monaco Investment Partners II, LP

 

 

2

 

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

(a)

(b)

 

3

 

SEC USE ONLY

 

 

 

4

 

SOURCE OF FUNDS

OO, PF 

 

 
5

Check if Disclosure of Legal Proceedings Is Required Pursuant to 
Items 2(d) or 2(e)

 

 
6

Citizenship or Place of Organization

Illinois, USA

 

 
NUMBER OF
SHARES
7

SOLE VOTING POWER

-0-

 

 
BENEFICIALLY
OWNED BY
8

SHARED VOTING POWER

2,055,754 shares of Common Stock (1)

 

EACH
REPORTING
9

SOLE DISPOSITIVE POWER

-0-

 

 
PERSON
WITH:
10

SHARED DISPOSITIVE POWER

2,055,754 shares of Common Stock (1)  

 

 

11

 

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

2,055,754 shares of Common Stock (1)

 

 

12

 

CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

Not applicable.  

 

 

 

13

 

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

12.2% of the outstanding Common Stock (1)

 

 

14

 

TYPE OF REPORTING PERSON

PN 

 

 
         

 

  (1)  Includes 100,000 shares of Common Stock issuable upon exercise of outstanding warrants to purchase shares of Common Stock with an exercise price of $2.00 per share held by the Reporting Person (the “ 100,000 Warrants ”).

 

 
 

 

CUSIP No. 609011101

 

 

 

1

 

NAME OF REPORTING PERSONS.
I.R.S. IDENTIFICATION NO. OF ABOVE  PERSONS (ENTITIES ONLY)

Donald P. Monaco Insurance Trust

 

 

2

 

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

(a)

(b)

 

3

 

SEC USE ONLY

 

 

 

4

 

SOURCE OF FUNDS

OO, PF 

 

 
5

Check if Disclosure of Legal Proceedings Is Required Pursuant to 
Items 2(d) or 2(e)

 

 
6

Citizenship or Place of Organization

Illinois, USA

 

 
NUMBER OF
SHARES
7

SOLE VOTING POWER

-0-

 

 
BENEFICIALLY
OWNED BY
8

SHARED VOTING POWER

2,081,292 shares of Common Stock (1)

 

EACH
REPORTING
9

SOLE DISPOSITIVE POWER

-0-

 

 
PERSON
WITH:
10

SHARED DISPOSITIVE POWER

2,081,292 shares of Common Stock (1)  

 

 

11

 

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

2,081,292 shares of Common Stock (1)

 

 

12

 

CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

Not applicable.  

 

 

 

13

 

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

12.4% of the outstanding Common Stock (1)

 

 

14

 

TYPE OF REPORTING PERSON

OO 

 

 
         

 

(1)  Includes 87,500 shares of Common Stock issuable upon exercise of outstanding warrants to purchase shares of Common Stock with an exercise price of $2.10 per share held by the Reporting Person (the “ 87,500 Warrants ” and collectively, with the 100,000 Warrants, the “ Warrants ”).

 

 
 

 

CUSIP No. 609011101

 

 

 

1

 

NAME OF REPORTING PERSONS.
I.R.S. IDENTIFICATION NO. OF ABOVE  PERSONS (ENTITIES ONLY)

Donald P. Monaco

 

 

2

 

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

(a)

(b)

 

3

 

SEC USE ONLY

 

 

 

4

 

SOURCE OF FUNDS

OO, PF 

 

 
5

Check if Disclosure of Legal Proceedings Is Required Pursuant to 
Items 2(d) or 2(e)

 

 
6

Citizenship or Place of Organization

United States

 

 
NUMBER OF
SHARES
7

SOLE VOTING POWER

-0-

 

 
BENEFICIALLY
OWNED BY
8

SHARED VOTING POWER

4,137,066 shares of Common Stock (1)

 

EACH
REPORTING
9

SOLE DISPOSITIVE POWER

-0-

 

 
PERSON
WITH:
10

SHARED DISPOSITIVE POWER

4,137,066 shares of Common Stock (1)  

 

 

11

 

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

4,137,066 shares of Common Stock (1)

 

 

12

 

CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

Not applicable.  

 

 

 

13

 

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

24.5% of the outstanding Common Stock (1)

 

14

 

TYPE OF REPORTING PERSON

IN 

 

 
         

 

(1)  Includes shares of Common Stock issuable upon exercise of the Warrants.

 

 
 

 

CUSIP No. 609011101

 

 

This Amendment No. 2 (the “ Amendment ”) amends and supplements the Schedule 13D filed with the Securities and Exchange Commission (the “ Commission ”) on November 3, 2016, as amended by Amendment No. 1 thereto filed with the Commission on March 9, 2017 (collectively, the “ Schedule 13D ”), by Monaco Investment Partners II, LP, an Illinois limited partnership (“ MI Partners ”), the Donald P. Monaco Insurance Trust, an Illinois trust (the “ Trust ”), and Donald P. Monaco, an individual (“ Monaco ”). Each of the foregoing are referred to as a “ Reporting Person ” and collectively as the “ Reporting Persons .” Capitalized terms used but not otherwise defined in this Amendment have the meanings ascribed to such terms in the Schedule 13D. Except as expressly amended and supplemented by this Amendment, the Schedule 13D is not amended or supplemented in any respect, and the disclosures set forth in the Schedule 13D, other than as amended herein are incorporated by reference herein.

Item 3. Source of Amount of Funds or Other Consideration

Effective on August 3, 2017, the Reporting Person converted 1,075,000 shares of the Company’s Series A 10% Cumulative Convertible Preferred Stock (“ Series A Preferred Stock ”) (including 575,000 shares held by MI Partners and 500,000 shares held by the Trust), on a 2-for-1 basis (as provided by the current terms of the Series A Preferred Stock), into 2,150,000 shares of Common Stock.

Effective on August 11, 2017, the Reporting Person (through the Trust), purchased 87,500 shares of Common Stock of the Issuer and warrants to acquire 87,500 shares of Common Stock of the Company with an exercise price of $2.10 per share, from the Company, for the purchase price of $2.00 per unit (one share and one warrant), pursuant to the terms of a July 31, 2017, Common Stock and Warrant Purchase Agreement.

The exercise price of the warrants is $2.10 per share, subject to adjustment as provided therein, and the warrants are exercisable from August 11, 2017 through July 30, 2022. The exercise price and number of shares of Common Stock issuable upon the exercise of the warrants will be subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, and will also be subject to weighted average anti-dilution adjustments in the event the Company issues or is deemed to have issued any securities below the then exercise price of the warrants, subject to certain exceptions, until August 2, 2018, each as described in greater detail in the warrants. After the six month anniversary of August 11, 2017, if a registration statement covering the issuance or resale of the shares of Common Stock issuable upon exercise of the warrants (the “ Warrant Shares ”) is not available for the issuance or resale, as applicable, the warrants may be exercised by means of a “cashless exercise.”

The Common Stock and Warrant Purchase Agreement and conversion of the Series A Preferred Stock is described in greater detail in the Company’s Current Report on Form 8-K, filed with the Commission on August 1, 2017.

Item 4. Purpose of Transaction

The Reporting Persons acquired the securities for investment purposes. In the future, depending on general market and economic conditions affecting the Company and other relevant factors, the Reporting Persons may purchase additional securities of the Company or dispose of some or all of the securities they currently own from time to time in open market transactions, private transactions or otherwise.

The Reporting Persons do not currently have any plans or proposals which relate to or would result in the following described:

 

  (a) the acquisition by persons of additional securities of the Company, or the disposition of securities of the Company;
     
  (b) a reorganization involving the Company;
     
  (c) a sale or transfer of a material amount of assets of the Company or any of its subsidiaries;
     
  (d) a change in the present board of directors and management of the Company, including plans or proposals to change the number or term of directors or to fill any existing vacancies on the board (otherwise than pursuant to agreements entered into in connection with the sale of the shares and warrants);
     
  (e) a material change in the present capitalization or dividend policy of the Company;
     
  (f) other material changes in the Company’s business or corporate structure;
     
  (g) changes in the Company’s charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Company by any person;

  

The Reporting Persons do not have any plans or proposals which relate to or result in:

 

  (h) causing a class of securities of the Company to be delisted from a national securities exchange or cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association;
     
  (i) a class of equity securities of the Company becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934; or
     
  (j) any action similar to any of those enumerated in (h) through (i), above.

 

 
 

 

CUSIP No. 609011101

 

 

Item 5. Interest in Securities of the Issuer 

  (a)

As of the close of business on August 11, 2017, the Reporting Persons beneficially own in aggregate 4,137,066 shares of Common Stock (1) , representing 24.5% of the outstanding Common Stock (1) .

As of the close of business on August 11, 2017, MI Partners beneficially owns in aggregate 2,055,754 shares of Common Stock (1) , representing 12.2% of the outstanding Common Stock (1) . By virtue of his relationship with MI Partners discussed in further detail in Item 2, Monaco is deemed to beneficially own the securities beneficially owned by MI Partners.

As of the close of business on August 11, 2017, the Trust beneficially owns in aggregate 2,081,292 shares of Common Stock (1) , representing 12.4% of the outstanding Common Stock (1) . By virtue of his relationship with the Trust discussed in further detail in Item 2, Monaco is deemed to beneficially own the securities beneficially owned by the Trust. 

     
  (b) Monaco may be deemed to have shared power with MI Partners and the Trust, to vote and dispose of the securities reported in this Schedule 13D beneficially owned by MI Partners and the Trust, respectively.
     
  (c) See Item 3, above.
     
  (d) No other person has the right to receive or the power to direct the receipt of dividends from or the proceeds from the sale of the securities beneficially owned by the Reporting Persons.
     
  (e) N/A.

 

(1)  Includes shares of Common Stock issuable upon exercise of the Warrants held by the Reporting Persons.

 

Item 6. Contracts, Arrangements, Understanding or Relationships with Respect to Securities of the Issuer

 

The Reporting Persons have entered into a Joint Filing Agreement pursuant to which, among other things, the parties agreed to the joint filing on behalf of each of them of statements on Schedule 13D with respect to the securities of the Issuer. The Joint Filing Agreement is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Except as set forth herein, there are no contracts, arrangements, understandings or relationships among the Reporting Persons, or between the Reporting Persons and any other person, with respect to the securities of the Issuer.

Item 7. Material to be Filed as Exhibits

 

Exhibit No.

 

 

Description

 

99.1   Joint Filing Agreement by and among Monaco Investment Partners II, LP, Donald P. Monaco Insurance Trust and Donald P. Monaco, dated August 14, 2017

 

 
 

 

CUSIP No. 609011101

 

 

Signatures

 

After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: August 14, 2017

 

Monaco Investment Partners II, LP
 
By: Donald P. Monaco, General Partner

 

 

/s/ Donald P. Monaco
  Donald P. Monaco

 

Donald P. Monaco Insurance Trust
 
  /s/ Donald P. Monaco
  Donald P. Monaco
Trustee

 

/s/ Donald P. Monaco
Donald P. Monaco

 

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of the filing person), evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement: provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.